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Hepatocellular carcinoma (HCC) has a poor prognosis because of its high recurrence 
rate.  Recently, vitamin K2 has been reported to inhibit the growth of HCC cell lines.  To 
clarify the preventive effect of vitamin K2 on HCC recurrence, we studied 72 HCC pa-
tients who had been treated with surgical resection, local ablation or transarterial embo-
lization:  their etiologies were hepatitis B virus (n = 21), hepatitis C virus (n = 47), both B 
and C viruses (n = 2) and non-B or non-C virus (n = 2).  We divided them into 2 groups: 
in one group, patients were treated with 45-mg/day vitamin K2 [K2-treated group (n = 
23)], and in another, patients were not given vitamin K2 or a placebo [non-treated con-
trol group (n = 49)].  The obtained results between the 2 groups were compared.  HCC 
recurred in 12 (52.2%) of the 23 K2-treated patients, and 22 (44.9%) of the 49 control 
patients.  The differences in cumulative recurrence-free rate and cumulative survival 
rate between both groups were not significant (P = 0.92 and P = 0.08, respectively).  As 
observed, chemopreventive effects of vitamin K2 at a clinically relevant dose on HCC re-
currence were ineffective after effective treatment for HCC.  Different regimens such as 
higher doses of vitamin K2 or combination therapy with other drugs may be worth test-
ing to further explore the preventive effect on HCC recurrence. 
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Hepatocellular carcinoma (HCC) is one of the 
most common malignancies worldwide.  In Japan, 
primary liver cancer, 95% of which is HCC, is 
ranked 3rd in men and 5th in women as a cause 
of death from malignant neoplasm.  Chronic vi-
ral hepatitis associated with hepatitis B virus and 
hepatitis C virus (HCV) is a major cause of HCC. 
In spite of curative treatments, including surgical 
resection and local ablation therapy, the recurrence 
rate in the remnant liver is high (Araii et al., 2000). 
Therefore, chemoprevention for the recurrence of 
HCC after curative treatment is important. 
 For chemopreventive therapy in patients 
with chronic HCV infection, interferon has been 
administrated and promising results have been 
obtained (Ikeda et al., 2000; Suou et al., 2001). 
Acyclic retinoid has been shown to prevent the 
recurrence of HCC after surgical resection or lo-
cal ablation therapy (Muto et al., 1996).  Vitamin 
K2 is known to inhibit the growth of a variety of 
tumor cells including hepatoma cells by induc-
ing apoptosis or differentiation (Miyazaki et al., 
2001).  Recently, Mizuta et al. reported the benefit 
of vitamin K2 on the recurrence and survival in 
patients with HCC after curative therapy (Mizuta 
et al., 2006).  To re-confirm their findings, we 
conducted a similar study after local ablation 
therapy or curative resection.
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Materials and Methods
 
Patients and study protocol
 
The study included 72 patients with HCC who 
were admitted to Tottori University Hospital be-
tween August 2002 and June 2006.  Diagnosis 
of HCC was confirmed by a combination of his-
topathological examination from biopsy speci-
mens, serological examination and findings with 
diagnostic imagings including contrast-enhanced 
computed tomography (CT), magnetic resonance 
imaging (MRI) and transhepatic arteriography. 
All patients underwent curative treatment includ-
ing surgical resection, percutaneous ethanol in-
jection or percutaneous radiofrequency ablation 
with or without transarterial chemoembolization. 
After 1 month of treatment, curative treatment 
was defined as no residual HCC visualized with 
any of the above described imagings.  In total, 72 
patients were enrolled in the present study.  The 
patients were assigned to a group treated with 
or another not treated with vitamin K2 (control 
group) based on the judgments by their physician 
in charge.  Vitamin K2, Glakay (Eisai, Tokyo, 
Japan), was given at a fixed dose of 45 mg/day 
during the follow-up periods.  Patients of the 
control group were not given a placebo.  Serum 
alfa-fetoprotein levels were measured with a com-
mercially available enzyme immunoassay kit 
(Abbott Japan, Tokyo), and protein induced by 
vitamin K absence or antagonist (PIVKA II) was 
tested with an ELISA kit (Picolumi PIVKA II 
kit, Sanko Junyaku, Tokyo).  Liver functions were 
estimated according to the Japan Integrated Stag-
ing (JIS) score (Kudo et al., 2003).  The JIS score 
is a new score system that includes 2 previous 
classifications, the TNM endorsed by the Union 
Internationale Contre le Cancer and the Child-
Pugh classification (Henderson et al., 2003).  The 
1st endpoint was the time to recurrence of HCC, 
which was diagnosed with imagings.  The 2nd 
endpoint was overall survival.  Contrast-enhanced 
CT scans or MRI was performed every 3 months 
after curative treatment.  Examinations were con-
tinued until the detection of recurrent HCC.  Alfa-
fetoprotein and PIVKA II were assayed monthly. 
The present study conformed to the ethical guide-
line of the Declaration of Helsinki.  Informed 
consent was verbally obtained from all patients.
 
Statistical methods
 
Statistical analysis was performed by standard 
methods.  The cumulative incidence of HCC recur-
rence and deaths were plotted using the Kaplan-
Meier method, and the statistical significance of 
differences was determined using the log-rank test 
(Cox regression analysis was used for univariate 
and multivariate analyses).  Differences with a P 
value < 0.05 were considered significant.  The data 
are shown as the mean ± SD. 
 
 
Results
 
Compliance with vitamin K2 in the K2-treated 
group was good.  No adverse effects were ob-
served and no patients dropped out of the study. 
Clinical characteristics are shown in Table 1. 
Twenty-three patients were enrolled in the K2-
treated group, and 49 patients were in the non-
treated control group.  The number of patients 
treated with surgical resection, local ablation 
therapy and transcatheter arterial chemoembo-
lization was 2, 7 and 14 in the K2-treated group, 
and 7, 18 and 24 in the control group, respectively. 
Differences in age, gender, observation periods, 
etiologies and HCC-related findings were not sig-
nificant between groups.  The JIS score showed 
no difference between groups.  The mean AFP 
level was 382.6 ± 22.4 ng/dL in the K2-treated 
group and 2267.5 ± 1747.8 ng/dL in the control 
group.  The mean PIVKA II level was 1182.9 ± 
960.9 mAU/mL, and 2421.3 ± 1413.4 mAU/mL, 
respectively.  The mean follow-up period was 23.8 
± 14.1 months (range, 0.5–45.6 months) for the 
K2-treated group, and 26.9 ± 10.9 months (range, 
3.3–43.7 months) for the control group.
Fig. 1.  Cumulative recurrence-free rates in patients.   
 a: HCC patients after curative treatment:       , K2-treated group (n = 23);      , control group (n = 49). 
 b: HCV-positive HCC patients after curative treatment:       , K2-treated group (n = 15);      , control group (n = 33).
Differences between groups are not significant both in a and b.  HCC, hepatocellular carcinoma; HCV, hepatitis C virus. 
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 The mean time to tumor recurrence was 16.3 
± 10.1 months in the K2-treated group and 10.4 
± 6.6 months in the control group, respectively. 
During the follow-up period, recurrent HCC 
was observed in 22 patients in the control group 
and in 12 patients in the K2-treated group.  The 
cumulative recurrence-free rates were 73.9% at 
12 months, 67.2% at 24 months and 21.9% at 36 
months in the K2-treated group, and were 50.6%, 
38.3% and 32.4% in the control group, respective-
ly (Fig. 1a).  The difference in cumulative recur-
rence-free rate was not significant between the 2 
groups (log-rank test; P = 0.92).  In HCV patients, 
the cumulative recurrence-free rates were 77.4% 
at 12 months, 46.4% at 24 months and 31.0% at 
36 months in the K2-treated group, and were 
47.9%, 40.5% and 36.0% in the control group, re-
spectively (log-rank test; P = 0.58, Fig. 1b). 
Table 1.  Characterstics of the patients enrolled in the present study
  Vitamin K2- Non-treated P 
  treated group control group 
  [23] [49]
Age   (year) 67 ± 9 69 ± 9 NS
Sex  (male/female) 11/12 27/22 NS
Observation period after HCC therapy  (month) 23.8 ± 14.1 26.9 ± 10.9 NS
Etiology       NS
  Hepatitis virus B   6 15
  Hepatitis virus C  14 33
  Hepatitis viruses B and C   2  0
  Non-hepatitis virus B or C   1  1
JIS score     NS
  0  1 8
  1  10 18
  2  9 14
  3  3 9
Characteristics of HCC
  Maximum diameter of tumor  (cm) 2.3 ± 0.9  2.8 ± 1.7 NS
  Number of nodules   1.3 ± 0.6  1.4 ± 0.9 NS
[  ], number of subjects.
HCC, hepatocellular carcinoma; mo, months; JIS, Japan Integrated Staging; NS, not significant.
P = 0.58
0 12 24 36 (month)
1.0
0.8
 
0.6
0.4
0.2
0.0
R
e
c
u
rr
e
n
c
e
 f
re
e
 r
a
te
b
P = 0.92
0 12 24 36 (month)
1.0
0
0.8
 
0.6
0.4
0.2
0.0
R
e
c
u
rr
e
n
c
e
 f
re
e
 r
a
te
a
Fig. 2.  Cumulative survival rates in patients. 
 a: HCC patients after curative treatment:       , K2-treated group (n = 23);      , control group (n = 49). 
 b: HCV-positive HCC patients after curative treatment:       , K2-treated group (n = 15);      , control group (n = 33).
Differences between groups are not significant both in a and b.  HCC, hepatocellular carcinoma; HCV, hepatitis C virus. 
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 During the follow-up period, 2 K2-treated 
patients and 16 control patients died.  The 2 K2-
treated patients and 12 of the 16 control patients 
died of cancer progression:  among the rest 4 con-
trol patients, 1 died of hepatic failure and 3 died of 
non-hepatic disease.  The cumulative survival rates 
for the K2-treated group were 100% at 12 months, 
93.3% at 24 months and 85.6% at 36 months.  The 
corresponding rates for the control group were 
93.3%, 79.1% and 56.5%, respectively.  The differ-
ence in survival rate was not significant between 
both groups (log-rank test; P = 0.08, Fig. 2a).  The 
cumulative survival rates of HCV patients were 
100% at 12 months, 100% at 24 months and 87.5% 
at 36 months in the K2-treated group; and 93.3%, 
72.6% and 56.9% in the control group, respec-
tively (log-rank test; P = 0.10, Fig. 2b).  Vitamin 
K2 treatment immediately decreased the PIVKA 
II level, which was kept within normal ranges (data 
not shown).  
 
 
Discussion
 
Vitamin K is a fat-soluble essential vitamin that 
activates blood coagulation factors by convert-
ing glutamic residues to -carboxy glutaminic 
residues.  The vitamin K family of molecules 
comprises the natural forms vitamin K1 (phyllo-
quinone) and vitamin K2 (menaquinones) and the 
synthetic form of vitamin K3 (menadione).  This 
vitamin K family has tumor inhibition properties 
in vitro (Lamson et al., 2003).  Recently, it has 
been shown that vitamin K, specifically vitamin 
K2, may have antiproliferative effects toward a 
variety of cancers including HCC (Nishikawa 
et al., 1995; Otsuka et al., 2004), and that it may 
cause differentiation in various human myeloid 
leukemia cell lines (Miyazawa et al., 2001), al-
though the mechanism of cell growth inhibitory 
effects has not been explained.  Mastumoto et al. 
reported that vitamin K2 inhibits the proliferation 
of HCC cells in vitro through a cell cycle arrest 
at the G1 phase and apoptosis (Mastumoto et al., 
2006). 
 Clinically, vitamin K2 treatment has been 
widely used for the treatment of osteoporosis in 
Japan.  Recently, Habu et al. revealed that vitamin 
K2 exerted a suppressive effect against the devel-
opment of HCC in women with HCV cirrhosis, 
who took vitamin K2 for osteoporosis (Habu et 
al., 2004).  Furthermore, Mizuta et al. reported 
that vitamin K2 treatment significantly decreased 
the recurrence rate of HCC and achieved a sig-
nificant improvement in the overall survival rate 
(Mizuta et al., 2006).  In the present study, we 
did not find preventive effects of vitamin K2 on 
HCC recurrence or improvement in the survival 
rate after curative treatment.  Although our study 
was not double-blinded or controlled, there were 
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no significant differences in age, gender, etiol-
ogy, observation period and characteristics of 
HCC between groups with and without vitamin 
K2 treatment.  In addition, the patient number, 
tumor characteristics and etiology were not differ-
ent from the previous study (Mizuta et al., 2006). 
More recently, Hotta et al. also reported that vita-
min K2 appeared not to be able to inhibit or delay 
the recurrence of HCC after curative treatment 
(Hotta et al., 2007), which our results agreed with. 
In the future, a large-scale study with a longer ob-
servation period is required to clarify the preven-
tive effect of vitamin K2 on recurrence of HCC. 
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